The United Laboratories International (HKG:3933) unit Zhuhai United Laboratories obtained approval for the new drug application of its TUL321 Capsules from the US Food and Drug Administration (FDA), according to a Tuesday Hong Kong bourse filing.
The FDA also accepted an application for the clinical trial registration of the drug.
The drug is intended to be used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, age-related macular degeneration, multiple sclerosis, and myasthenia gravis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments